VIVUS, Inc. (NASDAQ:VVUS)’s share price traded down 2.3% during mid-day trading on Tuesday . The stock traded as low as $0.42 and last traded at $0.42. 553,658 shares traded hands during trading, a decline of 17% from the average session volume of 667,467 shares. The stock had previously closed at $0.43.
Several equities analysts have recently issued reports on the company. ValuEngine lowered VIVUS from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research downgraded VIVUS from a “buy” rating to a “hold” rating in a report on Saturday, January 6th.
The firm has a market capitalization of $48.88, a price-to-earnings ratio of -1.41 and a beta of 0.57. The company has a debt-to-equity ratio of -24.71, a quick ratio of 6.34 and a current ratio of 6.80.
VIVUS (NASDAQ:VVUS) last announced its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03. VIVUS had a negative return on equity of 843.43% and a negative net margin of 46.67%. The company had revenue of $11.94 million during the quarter. sell-side analysts predict that VIVUS, Inc. will post -0.45 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in VVUS. Northern Trust Corp increased its holdings in shares of VIVUS by 16.8% in the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 39,473 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of VIVUS by 166.2% in the third quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 246,927 shares in the last quarter. Macquarie Group Ltd. bought a new stake in shares of VIVUS in the third quarter worth about $192,000. OxFORD Asset Management LLP increased its holdings in shares of VIVUS by 14.0% in the third quarter. OxFORD Asset Management LLP now owns 1,059,382 shares of the biopharmaceutical company’s stock worth $1,040,000 after acquiring an additional 129,871 shares in the last quarter. Finally, Creative Planning increased its holdings in shares of VIVUS by 1,691.3% in the fourth quarter. Creative Planning now owns 366,706 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 346,235 shares in the last quarter. Institutional investors own 24.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “VIVUS (VVUS) Shares Down 2.3%” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/03/20/vivus-vvus-shares-down-2-3.html.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.